Epizyme ROE 2024

Epizyme ROE

12.14

Epizyme Dividend yield

Ticker

EPZM

ISIN

US29428V1044

WKN

A1T9L2

In 2024, Epizyme's return on equity (ROE) was 12.14, a 0% increase from the 0 ROE in the previous year.

Epizyme Aktienanalyse

What does Epizyme do?

Epizyme Inc is an American biotechnology company specializing in the development of therapeutic products for the treatment of cancer and genetic metabolic disorders. The company was founded in 2007 in Cambridge, Massachusetts. Epizyme focuses on developing drugs that target epigenetic changes in cells, which are changes in gene expression caused by changes in DNA structure. Epizyme specializes in the development of inhibitors of histone deacetylase enzymes (HDAC), which suppress the activity of enzymes involved in cell cycle regulation, apoptosis, and DNA repair. The company is divided into different business units focusing on different therapy areas, including oncology, hematologic oncology, and genetic metabolic disorders. In the field of oncology, Epizyme develops drugs for the treatment of blood and lymphatic system cancers such as diffuse large B-cell lymphoma and T-cell lymphoma. In the field of hematologic oncology, the company develops drugs for the treatment of blood disorders like myelodysplastic syndrome and acute myeloid leukemia. In the field of genetic metabolic disorders, Epizyme develops drugs for the treatment of lysosomal storage diseases. The company's business model primarily involves developing its own therapy products and collaborating with other biopharmaceutical companies and the pharmaceutical industry. Epizyme is listed on NASDAQ under the ticker symbol EPZM and has raised over $230 million in funding. Overall, Epizyme is an innovative company with a promising pipeline of drug candidates that works closely with other industry players to achieve its goals. It has established itself as a key player in the biotechnology industry. Epizyme ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Epizyme's Return on Equity (ROE)

Epizyme's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Epizyme's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Epizyme's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Epizyme’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Epizyme Stock

What is the ROE (Return on Equity) of Epizyme this year?

The ROE of Epizyme this year is 12.14 undefined.

How has the Return on Equity (ROE) of Epizyme developed compared to the previous year?

The ROE of Epizyme has increased by 0% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Epizyme?

A high ROE indicates that Epizyme generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Epizyme?

A low ROE can indicate that Epizyme is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Epizyme affect the company?

A change in ROE (Return on Equity) of Epizyme can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Epizyme?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Epizyme?

Some factors that can influence Epizyme's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Epizyme pay?

Over the past 12 months, Epizyme paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Epizyme is expected to pay a dividend of 0 USD.

What is the dividend yield of Epizyme?

The current dividend yield of Epizyme is .

When does Epizyme pay dividends?

Epizyme pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Epizyme?

Epizyme paid dividends every year for the past 0 years.

What is the dividend of Epizyme?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Epizyme located?

Epizyme is assigned to the 'Health' sector.

Wann musste ich die Aktien von Epizyme kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Epizyme from 6/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/1/2024.

When did Epizyme pay the last dividend?

The last dividend was paid out on 6/1/2024.

What was the dividend of Epizyme in the year 2023?

In the year 2023, Epizyme distributed 0 USD as dividends.

In which currency does Epizyme pay out the dividend?

The dividends of Epizyme are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Epizyme stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Epizyme

Our stock analysis for Epizyme Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Epizyme Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.